Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Cancer Pain-Pipeline Review, H1 2015

Cancer Pain-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Cancer Pain-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Cancer Pain-Pipeline Review, H1 2015', provides an overview of the Cancer Pain's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Cancer Pain

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Cancer Pain and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Cancer Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Cancer Pain pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Cancer Pain

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Cancer Pain pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Cancer Pain Overview 8

Therapeutics Development 9

Pipeline Products for Cancer Pain-Overview 9

Pipeline Products for Cancer Pain-Comparative Analysis 10

Cancer Pain-Therapeutics under Development by Companies 11

Cancer Pain-Therapeutics under Investigation by Universities/Institutes 15

Cancer Pain-Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Unknown Stage Products 19

Cancer Pain-Products under Development by Companies 20

Cancer Pain-Products under Investigation by Universities/Institutes 23

Cancer Pain-Companies Involved in Therapeutics Development 24

Amgen Inc. 24

Amorsa Therapeutics Inc. 25

AngioChem Inc. 26

Aphios Corporation 27

AstraZeneca Plc 28

BCN Peptides, S.A. 29

Benitec Biopharma Limited 30

BioDelivery Sciences International, Inc. 31

ChironWells GmbH 32

Daiichi Sankyo Company, Limited 33

Grunenthal GmbH 34

GW Pharmaceuticals Plc 35

Immupharma Plc 36

IntelGenx Corp. 37

Kolon Life Science, Inc. 38

Nektar Therapeutics 39

Neurocentrx Pharma Ltd. 40

Nippon Kayaku Co., Ltd. 41

Northern Light Pharmaceuticals AB 42

Orion Oyj 43

Pain Therapeutics, Inc. 44

Pfizer Inc. 45

Pharmaleads 46

Recordati S.p.A. 47

Sorrento Therapeutics, Inc. 48

Virobay Inc. 49

Winston Pharmaceuticals, Inc. 50

Zynerba Pharmaceuticals, Inc. 51

Cancer Pain-Therapeutics Assessment 52

Assessment by Monotherapy Products 52

Assessment by Target 53

Assessment by Mechanism of Action 55

Assessment by Route of Administration 57

Assessment by Molecule Type 59

Drug Profiles 62

AMS-410 ER12-Drug Profile 62

ANG-2002-Drug Profile 63

BBI-11008-Drug Profile 64

calpastatin-Drug Profile 65

cebranopadol-Drug Profile 66

crotalphine-Drug Profile 68

DD-04107-Drug Profile 69

dexmedetomidine hydrochloride-Drug Profile 70

dronabinol-Drug Profile 72

Drug for Cancer Neuropathic Pain-Drug Profile 73

fentanyl-Drug Profile 74

fentanyl citrate-Drug Profile 75

fentanyl citrate-Drug Profile 76

fulranumab-Drug Profile 77

HS-198-Drug Profile 80

hydromorphone hydrochloride-Drug Profile 81

INT-0028-Drug Profile 82

IPP-102199-Drug Profile 83

ketamine hydrochloride ER-Drug Profile 84

KLS-2010-Drug Profile 85

methadone hydrochloride-Drug Profile 86

nabiximols-Drug Profile 87

Nervarna-Drug Profile 90

NKTR-192-Drug Profile 92

Peptide to Block Voltage-Dependent N-Type Calcium Channel for Cancer Pain and Fibromyalgia-Drug Profile 93

PGN-202-Drug Profile 94

PL-265-Drug Profile 95

Q-201-Drug Profile 96

QX-314-Drug Profile 97

resiniferatoxin-Drug Profile 98

saracatinib difumarate-Drug Profile 99

Small Molecule 1 to Block Sodium Channels for Cancer Pain and Epilepsy-Drug Profile 101

Small Molecule 2 to Block Sodium Channels for Cancer Pain and Epilepsy-Drug Profile 102

Small Molecule 3 to Block Sodium Channels for Cancer Pain and Epilepsy-Drug Profile 103

Small Molecule to Antagonize Chemokine Receptor for Cancer Pain-Drug Profile 104

tanezumab-Drug Profile 105

VBY-825-Drug Profile 107

zucapsaicin-Drug Profile 108

ZYN-001-Drug Profile 110

Cancer Pain-Recent Pipeline Updates 111

Cancer Pain-Dormant Projects 122

Cancer Pain-Discontinued Products 126

Cancer Pain-Product Development Milestones 128

Featured News & Press Releases 128

Appendix 133

Methodology 133

Coverage 133

Secondary Research 133

Primary Research 133

Expert Panel Validation 133

Contact Us 133

Disclaimer 134

List of Tables

Number of Products under Development for Cancer Pain, H1 2015 12

Number of Products under Development for Cancer Pain-Comparative Analysis, H1 2015 13

Number of Products under Development by Companies, H1 2015 15

Number of Products under Development by Companies, H1 2015 (Contd..1) 16

Number of Products under Development by Companies, H1 2015 (Contd..2) 17

Number of Products under Investigation by Universities/Institutes, H1 2015 18

Comparative Analysis by Late Stage Development, H1 2015 19

Comparative Analysis by Clinical Stage Development, H1 2015 20

Comparative Analysis by Early Stage Development, H1 2015 21

Comparative Analysis by Unknown Stage Development, H1 2015 22

Products under Development by Companies, H1 2015 23

Products under Development by Companies, H1 2015 (Contd..1) 24

Products under Development by Companies, H1 2015 (Contd..2) 25

Products under Investigation by Universities/Institutes, H1 2015 26

Cancer Pain-Pipeline by Amgen Inc., H1 2015 27

Cancer Pain-Pipeline by Amorsa Therapeutics Inc., H1 2015 28

Cancer Pain-Pipeline by AngioChem Inc., H1 2015 29

Cancer Pain-Pipeline by Aphios Corporation, H1 2015 30

Cancer Pain-Pipeline by AstraZeneca Plc, H1 2015 31

Cancer Pain-Pipeline by BCN Peptides, S.A., H1 2015 32

Cancer Pain-Pipeline by Benitec Biopharma Limited, H1 2015 33

Cancer Pain-Pipeline by BioDelivery Sciences International, Inc., H1 2015 34

Cancer Pain-Pipeline by ChironWells GmbH, H1 2015 35

Cancer Pain-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 36

Cancer Pain-Pipeline by Grunenthal GmbH, H1 2015 37

Cancer Pain-Pipeline by GW Pharmaceuticals Plc, H1 2015 38

Cancer Pain-Pipeline by Immupharma Plc, H1 2015 39

Cancer Pain-Pipeline by IntelGenx Corp., H1 2015 40

Cancer Pain-Pipeline by Kolon Life Science, Inc., H1 2015 41

Cancer Pain-Pipeline by Nektar Therapeutics, H1 2015 42

Cancer Pain-Pipeline by Neurocentrx Pharma Ltd., H1 2015 43

Cancer Pain-Pipeline by Nippon Kayaku Co., Ltd., H1 2015 44

Cancer Pain-Pipeline by Northern Light Pharmaceuticals AB, H1 2015 45

Cancer Pain-Pipeline by Orion Oyj, H1 2015 46

Cancer Pain-Pipeline by Pain Therapeutics, Inc., H1 2015 47

Cancer Pain-Pipeline by Pfizer Inc., H1 2015 48

Cancer Pain-Pipeline by Pharmaleads , H1 2015 49

Cancer Pain-Pipeline by Recordati S.p.A., H1 2015 50

Cancer Pain-Pipeline by Sorrento Therapeutics, Inc., H1 2015 51

Cancer Pain-Pipeline by Virobay Inc., H1 2015 52

Cancer Pain-Pipeline by Winston Pharmaceuticals, Inc., H1 2015 53

Cancer Pain-Pipeline by Zynerba Pharmaceuticals, Inc., H1 2015 54

Assessment by Monotherapy Products, H1 2015 55

Number of Products by Stage and Target, H1 2015 57

Number of Products by Stage and Mechanism of Action, H1 2015 59

Number of Products by Stage and Route of Administration, H1 2015 61

Number of Products by Stage and Molecule Type, H1 2015 64

Cancer Pain Therapeutics-Recent Pipeline Updates, H1 2015 114

Cancer Pain-Dormant Projects, H1 2015 125

Cancer Pain-Dormant Projects (Contd..1), H1 2015 126

Cancer Pain-Dormant Projects (Contd..2), H1 2015 127

Cancer Pain-Dormant Projects (Contd..3), H1 2015 128

Cancer Pain-Discontinued Products, H1 2015 129

Cancer Pain-Discontinued Products (Contd..1), H1 2015 130

List of Figures

Number of Products under Development for Cancer Pain, H1 2015 12

Number of Products under Development for Cancer Pain-Comparative Analysis, H1 2015 13

Number of Products under Development by Companies, H1 2015 14

Comparative Analysis by Late Stage Development, H1 2015 19

Comparative Analysis by Clinical Stage Development, H1 2015 20

Comparative Analysis by Early Stage Products, H1 2015 21

Assessment by Monotherapy Products, H1 2015 55

Number of Products by Top 10 Targets, H1 2015 56

Number of Products by Stage and Top 10 Targets, H1 2015 56

Number of Products by Top 10 Mechanism of Actions, H1 2015 58

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 58

Number of Products by Top 10 Routes of Administration, H1 2015 60

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 60

Number of Products by Top 10 Molecule Types, H1 2015 62

Number of Products by Stage and Top 10 Molecule Types, H1 2015 63

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Amgen Inc.

Amorsa Therapeutics Inc.

AngioChem Inc.

Aphios Corporation

AstraZeneca Plc

BCN Peptides, S.A.

Benitec Biopharma Limited

BioDelivery Sciences International, Inc.

ChironWells GmbH

Daiichi Sankyo Company, Limited

Grunenthal GmbH

GW Pharmaceuticals Plc

Immupharma Plc

IntelGenx Corp.

Kolon Life Science, Inc.

Nektar Therapeutics

Neurocentrx Pharma Ltd.

Nippon Kayaku Co., Ltd.

Northern Light Pharmaceuticals AB

Orion Oyj

Pain Therapeutics, Inc.

Pfizer Inc.

Pharmaleads

Recordati S.p.A.

Sorrento Therapeutics, Inc.

Virobay Inc.

Winston Pharmaceuticals, Inc.

Zynerba Pharmaceuticals, Inc.

Cancer Pain Therapeutic Products under Development, Key Players in Cancer Pain Therapeutics, Cancer Pain Pipeline Overview, Cancer Pain Pipeline, Cancer Pain Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com